FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100080478> ?p ?o ?g. }

• W2100080478 abstract "Severe TBI, defined as a Glasgow Coma Scale ≤ 8, increases intracranial pressure and activates the sympathetic nervous system. Sympathetic hyperactivity after TBI manifests as catecholamine excess, hypertension, abnormal heart rate variability, and agitation, and is associated with poor neuropsychological outcome. Propranolol and clonidine are centrally acting drugs that may decrease sympathetic outflow, brain edema, and agitation. However, there is no prospective randomized evidence available demonstrating the feasibility, outcome benefits, and safety for adrenergic blockade after TBI. The DASH after TBI study is an actively accruing, single-center, randomized, double-blinded, placebo-controlled, two-arm trial, where one group receives centrally acting sympatholytic drugs, propranolol (1 mg intravenously every 6 h for 7 days) and clonidine (0.1 mg per tube every 12 h for 7 days), and the other group, double placebo, within 48 h of severe TBI. The study uses a weighted adaptive minimization randomization with categories of age and Marshall head CT classification. Feasibility will be assessed by ability to provide a neuroradiology read for randomization, by treatment contamination, and by treatment compliance. The primary endpoint is reduction in plasma norepinephrine level as measured on day 8. Secondary endpoints include comprehensive plasma and urine catecholamine levels, heart rate variability, arrhythmia occurrence, infections, agitation measures using the Richmond Agitation-Sedation Scale and Agitated Behavior scale, medication use (anti-hypertensive, sedative, analgesic, and antipsychotic), coma-free days, ventilator-free days, length of stay, and mortality. Neuropsychological outcomes will be measured at hospital discharge and at 3 and 12 months. The domains tested will include global executive function, memory, processing speed, visual-spatial, and behavior. Other assessments include the Extended Glasgow Outcome Scale and Quality of Life after Brain Injury scale. Safety parameters evaluated will include cardiac complications. The DASH After TBI Study is the first randomized, double-blinded, placebo-controlled trial powered to determine feasibility and investigate safety and outcomes associated with adrenergic blockade in patients with severe TBI. If the study results in positive trends, this could provide pilot evidence for a larger multicenter randomized clinical trial. If there is no effect of therapy, this trial would still provide a robust prospective description of sympathetic hyperactivity after TBI. ClinicalTrials.gov NCT01322048" @default.
• W2100080478 created "2016-06-24" @default.
• W2100080478 creator A5005268714 @default.
• W2100080478 creator A5018571955 @default.
• W2100080478 creator A5022648071 @default.
• W2100080478 creator A5028592475 @default.
• W2100080478 creator A5050680784 @default.
• W2100080478 creator A5055926991 @default.
• W2100080478 creator A5060370062 @default.
• W2100080478 date "2012-09-26" @default.
• W2100080478 modified "2023-10-11" @default.
• W2100080478 title "Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial" @default.
• W2100080478 cites W1542867885 @default.
• W2100080478 cites W1963883722 @default.
• W2100080478 cites W1965615535 @default.
• W2100080478 cites W1975474352 @default.
• W2100080478 cites W1976852930 @default.
• W2100080478 cites W1979605554 @default.
• W2100080478 cites W1984070033 @default.
• W2100080478 cites W1984170705 @default.
• W2100080478 cites W1986988690 @default.
• W2100080478 cites W1987877973 @default.
• W2100080478 cites W1989607719 @default.
• W2100080478 cites W1991041899 @default.
• W2100080478 cites W1995499577 @default.
• W2100080478 cites W2000366267 @default.
• W2100080478 cites W2002072526 @default.
• W2100080478 cites W2009750859 @default.
• W2100080478 cites W2011611283 @default.
• W2100080478 cites W2020477707 @default.
• W2100080478 cites W2026269968 @default.
• W2100080478 cites W2026532831 @default.
• W2100080478 cites W2030506058 @default.
• W2100080478 cites W2032138778 @default.
• W2100080478 cites W2042791920 @default.
• W2100080478 cites W2048501744 @default.
• W2100080478 cites W2052621814 @default.
• W2100080478 cites W2056884334 @default.
• W2100080478 cites W2064344765 @default.
• W2100080478 cites W2064839408 @default.
• W2100080478 cites W2065235650 @default.
• W2100080478 cites W2082311304 @default.
• W2100080478 cites W2083347584 @default.
• W2100080478 cites W2088631845 @default.
• W2100080478 cites W2092238508 @default.
• W2100080478 cites W2092241603 @default.
• W2100080478 cites W2093274439 @default.
• W2100080478 cites W2093438032 @default.
• W2100080478 cites W2094233062 @default.
• W2100080478 cites W2094741545 @default.
• W2100080478 cites W2100128709 @default.
• W2100080478 cites W2108696783 @default.
• W2100080478 cites W2135672238 @default.
• W2100080478 cites W2141188392 @default.
• W2100080478 cites W2154459661 @default.
• W2100080478 cites W2166403437 @default.
• W2100080478 doi "https://doi.org/10.1186/1745-6215-13-177" @default.
• W2100080478 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3517360" @default.
• W2100080478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23013802" @default.
• W2100080478 hasPublicationYear "2012" @default.
• W2100080478 type Work @default.
• W2100080478 sameAs 2100080478 @default.
• W2100080478 citedByCount "56" @default.
• W2100080478 countsByYear W21000804782014 @default.
• W2100080478 countsByYear W21000804782015 @default.
• W2100080478 countsByYear W21000804782016 @default.
• W2100080478 countsByYear W21000804782017 @default.
• W2100080478 countsByYear W21000804782018 @default.
• W2100080478 countsByYear W21000804782019 @default.
• W2100080478 countsByYear W21000804782020 @default.
• W2100080478 countsByYear W21000804782021 @default.
• W2100080478 countsByYear W21000804782022 @default.
• W2100080478 countsByYear W21000804782023 @default.
• W2100080478 crossrefType "journal-article" @default.
• W2100080478 hasAuthorship W2100080478A5005268714 @default.
• W2100080478 hasAuthorship W2100080478A5018571955 @default.
• W2100080478 hasAuthorship W2100080478A5022648071 @default.
• W2100080478 hasAuthorship W2100080478A5028592475 @default.
• W2100080478 hasAuthorship W2100080478A5050680784 @default.
• W2100080478 hasAuthorship W2100080478A5055926991 @default.
• W2100080478 hasAuthorship W2100080478A5060370062 @default.
• W2100080478 hasBestOaLocation W21000804781 @default.
• W2100080478 hasConcept C118552586 @default.
• W2100080478 hasConcept C126322002 @default.
• W2100080478 hasConcept C142724271 @default.
• W2100080478 hasConcept C168563851 @default.
• W2100080478 hasConcept C17624336 @default.
• W2100080478 hasConcept C203092338 @default.
• W2100080478 hasConcept C204243189 @default.
• W2100080478 hasConcept C204787440 @default.
• W2100080478 hasConcept C27081682 @default.
• W2100080478 hasConcept C2776153860 @default.
• W2100080478 hasConcept C2778399450 @default.
• W2100080478 hasConcept C2781017439 @default.
• W2100080478 hasConcept C42219234 @default.
• W2100080478 hasConcept C71924100 @default.
• W2100080478 hasConceptScore W2100080478C118552586 @default.
• W2100080478 hasConceptScore W2100080478C126322002 @default.
• W2100080478 hasConceptScore W2100080478C142724271 @default.
• W2100080478 hasConceptScore W2100080478C168563851 @default.

• next